Company

Relmada Therapeutics, Inc.

Headquarters: New York, NY, United States

Employees: 14

CEO: Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA

NASDAQ: RLMD +5.61%

Market Cap

$11.7 Million

USD as of Jan. 1, 2025

Market Cap History

Relmada Therapeutics, Inc. Categories

United States Healthcare Drug Manufacturers—Specialty & Generic
United States Healthcare United States Drug Manufacturers—Specialty & Generic

Relmada Therapeutics, Inc. market capitalization over time

Evolution of Relmada Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Relmada Therapeutics, Inc.

Top Competitors by Market Capitalization

Industry: Drug Manufacturers—Specialty & Generic
Company Market Cap (USD)
Zoetis Inc. $75.33 B
MERCK Kommanditgesellschaft auf Aktien $65.17 B
Haleon plc $42.16 B
Takeda Pharmaceutical Company Limited $41.47 B
Teva Pharmaceutical Industries Limited $18.95 B
Sector:
Company Market Cap (USD)
Lilly $689.42 B
Novo Nordisk $622.07 B
UnitedHealth Group $487.54 B
Johnson & Johnson $353.05 B
AbbVie $301.60 B

Detailed Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead program is REL-1017, is a new chemical entity and novel N-methyl-D-aspartate receptor channel blocker for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is based in Coral Gables, Florida.

Stocks & Indices

Relmada Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: RLMD wb_incandescent

Details

Headquarters:

880 Third Avenue

12th Floor

New York, NY 10022

United States

Phone: 646 876 3459